← Oncology Approval Tracker

FDA DECISION ·

Imbruvica

ibrutinib · Pharmacyclics / AbbVie

FDA approvalNew or expanded indicationChronic graft-versus-host disease
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Treatment of chronic graft-versus-host disease after failure of at least one line of systemic therapy in patients age one or older, expanding the prior adult use.

LAMPGEN ANALYSIS

Why it matters

The expansion provides a pediatric systemic option after prior treatment failure.

What research teams should watch

Document transplant and prior systemic therapy, then verify pediatric dose and formulation with the transplant team.

PRIMARY RECORDS

Sources